Lupin Ltd announced today that it has acquired Hormosan Pharma GmbH (Hormosan), a German Sales and Marketing generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS).
Hormosan, with total sales of Euro 6.8 Million for the year ended December 2007, develops, licenses and markets a range of generics in Germany. Hormosan has a complementary product portfolio with products in the Central Nervous System and Cardiovascular therapeutic segments. Hormosan has created a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector.
Besides strong key account management the company also has a successful in Regulatory team, Pharmacovigilance, Medical Information and Marketing teams.
Commenting on the acquisition, Dr. Desh Bandhu Gupta, Chairman, Lupin said, "This is in line with our M & A strategy to harness the potential of the leading global pharma markets. This move establishes a bridgehead in Germany and is our first acquisition in the important European market. Hormosan has strengths in the sales and marketing of its products nationwide, together with strong regulatory and pharmacovigilance capabilities that can strengthen our European know-how.
Lupin will be able to add significant value through its strengths in R & D and strong, complementary pipeline leading to major synergies and growth.
0 comments:
Post a Comment